The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000664347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/05/2026
Date registered
Help: Date registered
4/06/2026
Date last updated
Help: Date last updated
4/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Primary Biliary Cholangitis (PBC) Registry for assessment and change in quality of care in Australia
Scientific title
Primary Biliary Cholangitis (PBC) Australian Registry for Epidemiology & Quality of Care (PBCARE-QC)
Additional trial identifiers [1] 317204 0
Nil
Universal Trial Number (UTN)
U1111-1340-2760
Trial acronym
PBCARE-QC (Primary Biliary Cholangitis (PBC) Australian Registry for Epidemiology & Quality of Care)
Related trial records

Health condition
Health condition(s) studied:
Primary Biliary Cholangitis 341791 0
Hepatic Fibrosis 341792 0
Cirrhosis 341793 0
Liver Transplantation 341794 0
Condition category
Condition code
Inflammatory and Immune System 337867 337867 0 0
Autoimmune diseases
Oral and Gastrointestinal 337868 337868 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Observational
Patient registry
True
Target follow-up duration
5
Target follow-up type
Years
Description of the intervention or exposure
No direct patient involvement, this study is collecting data both retrospectively and prospectively from patient records including investigation results.
Data on hospital out-patient and in-patient visits will be recorded (when relevant to PBC) as well as treatments prescribed including dose and timing and date of initiation and cessation. There is no requirement for participants to complete any additional questionnaires or other physical assessment beyond that decided by the treating clinician as part of usual or best practice care.
The initial period of observation for the prospective cohort will be 5 years contingent on a satisfactory report to the ethics committee after 2 years.
The retrospective data will be from medical records including clinical notes and pathology systems to insure that patients fulfil the inclusion criteria for PBC and to establish date of diagnosis, stage of disease and past therapies employed. Patients with PBC seen in the preceding 13 months to site initiation will be included in the retrospective cohort.
Intervention code [1] 333973 0
Not applicable
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345326 0
Proportion of patients achieving the Quality of Indicators appropriate to the individual patient's PBC journey. Acknowledging that each patient is at a different time-point in their health journey and that some of the Quality of Care Indicators (QoCIs) will not be applicable. Some examples of QoCIs to be employed include: 1. > 90% patients with PBC are on appropriate weight-based dosage of URSO
Timepoint [1] 345326 0
at the time of clinical review, then yearly for up to 5 years
Primary outcome [2] 345547 0
2. > 90 % patients on URSO are monitored for URSO refractory disease at least 6 monthly
Timepoint [2] 345547 0
at the time of clinical review, then yearly for up to 5 years
Primary outcome [3] 345548 0
3. > 90 % of patients have a baseline record of fibrosis stage
Timepoint [3] 345548 0
at the time of clinical review, then yearly for up to 5 years
Secondary outcome [1] 461300 0
Uptake of second line therapies for PBC including time to initiation of therapy. These second-line therapies include: Elafibranor Obeticholic acid Seladelpar Fenofibrate Bezafibrate
Timepoint [1] 461300 0
at the time of clinical review, then yearly for up to 5 years,

Eligibility
Key inclusion criteria
• Adults (greater or equal to 18 years of age) with a confirmed diagnosis of PBC according to internationally accepted criteria:
• Positive anti-mitochondrial antibody (AMA), OR
• Positive disease-specific antinuclear antibodies (gp210, sp100, PML, M2), OR
• Characteristic liver histology in AMA-negative disease AND
• Elevated ALP of 1.5 × ULN (upper limit of normal) on at least two occasions >3 months apart.

Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Overlap syndromes (PBC–AIH overlap, PSC–AIH overlap).
• Prior liver transplant (unless included for quality-of-care evaluation in transplant clinics, analysed separately).
• Insufficient medical record documentation (<6 months follow-up).

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Both
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 321784 0
Commercial sector/Industry
Name [1] 321784 0
IPSEN
Country [1] 321784 0
Australia
Funding source category [2] 321786 0
Commercial sector/Industry
Name [2] 321786 0
Gilead
Country [2] 321786 0
United States of America
Primary sponsor type
Hospital
Name
Bayside Health (Alfred Hospital)
Address
Country
Australia
Secondary sponsor category [1] 324630 0
None
Name [1] 324630 0
Address [1] 324630 0
Country [1] 324630 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320328 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320328 0
Ethics committee country [1] 320328 0
Australia
Date submitted for ethics approval [1] 320328 0
26/02/2026
Approval date [1] 320328 0
30/03/2026
Ethics approval number [1] 320328 0
Central ID: 121749

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150106 0
A/Prof John Lubel
Address 150106 0
Department of Gastroenterology, Alfred Health, 55 Commercial Road, Melbourne, Victoria, 3004
Country 150106 0
Australia
Phone 150106 0
+61 03 9076 2583
Fax 150106 0
Email 150106 0
Contact person for public queries
Name 150107 0
Joanne Mitchell
Address 150107 0
Department of Gastroenterology, Alfred Health, 55 Commercial Road, Melbourne, Victoria, 3004
Country 150107 0
Australia
Phone 150107 0
+61 03 9076 2583
Fax 150107 0
Email 150107 0
Contact person for scientific queries
Name 150108 0
Joanne Mitchell
Address 150108 0
Department of Gastroenterology, Alfred Health, 55 Commercial Road, Melbourne, Victoria, 3004
Country 150108 0
Australia
Phone 150108 0
+61 03 9076 2583
Fax 150108 0
Email 150108 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual participant anonymity is mandatory



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    __ETHICS CERTIFICATE OF APPROVAL.pdf
Study protocol    1. Study Protocol FINAL V1.1 03_3_26.pdf
Other    4. DATA ACCESS POLICY FINAL V1.0 - 03_3_26.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.